PharmX Technologies (ASX:PHX) ROCE %: -4.98% (As of Dec. 2025)

What is PharmX Technologies ROCE %?

PharmX Technologies ASX:PHX 40 ROCE % is -4.98% as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PharmX Technologies's annualized ROCE % for the quarter that ended in Dec. 2025 was -4.98%.

PharmX Technologies (ASX:PHX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PharmX Technologies ROCE % Related Terms

PharmX Technologies ROCE % Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies ROCE % Chart

PharmX Technologies Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

ROCE %

Get a 7-Day Free Trial

7.73

1.46

-2.67

1.16

0.63

PharmX Technologies Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															4.12	-2.13	4.62	-3.43	-4.98

40GF Score

PharmX Technologies Ltd ASX:PHX

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PharmX Technologies ROCE % Calculation

PharmX Technologies's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	0.11	/	( ( (29.857 - 11.95)	+	(18.825 - 1.73) )	/ 2 )
	=	0.11	/	( (17.907	+	17.095)	/ 2 )
	=	0.11	/	17.501
	=	0.63 %

PharmX Technologies's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	-0.838	/	( ( (18.825 - 1.73)	+	(18.006 - 1.419) )	/ 2 )
	=	-0.838	/	( ( 17.095	+	16.587 )	/ 2 )
	=	-0.838	/	16.841
	=	-4.98 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -4.98% mean?

PharmX Technologies (ASX:PHX) has a ROCE % of -4.98% as of Dec. 2025.

Is PharmX Technologies' ROCE % too high?

PharmX Technologies' current ROCE % is -4.98%. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does PharmX Technologies' ROCE % compare to VEEV and BTSG?

PharmX Technologies' ROCE % of -4.98% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Healthcare Providers & Services company?

The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current ROCE % is -4.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PharmX Technologies stock overvalued right now?

Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.13 — trading 85.7% above its estimated fair value. The current ROCE % is -4.98%. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current ROCE % is -4.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

ROCE %: -4.98%
GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies ASX:M7T ASX:BB1 ASX:SHG ASX:EMD ASX:PCK ASX:TRI ASX:BMT ASX:ALC ASX:PKY ASX:RHT VEEV BTSG ASX:PME TEM HQY TSE:2413 HKSE:02228 HNGE DOCS WAY

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000

Website https://www.pharmx.com.au

PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.

40GF Score

Get the complete analysis for ASX:PHX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13

Price

A$0.07

GF Value

View ASX:PHX Analysis

See ROCE % data for all stocks →